TSX:ONC 1.42 CAD -0.08 -5.33% Volume: 71,060 September 2, 2014
NASDAQ:ONCY 1.30 USD -0.08 -5.8% Volume: 441,111 September 2, 2014

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

September 02, 2014 Media Advisory - Oncolytics Biotech® Inc. to Participate in the Baird 2014 Health Care Conference
August 11, 2014 Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming Conferences
August 07, 2014 Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results
Sign up to receive e-mail updates *